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INTRODUCTION
Invasive fungal infections are major causes of morbidity
and mortality in the bone marrow transplant (BMT) set-
ting. Improved understanding of changes in the spectrum of
pathogens and risk factors for infection, along with recogni-
tion of nosocomial transmission as a major mode of infec-
tion, and the introduction of new therapeutic agents have
necessitated changes in the way the clinician approaches
this problem.
THE BIOLOGY OF FUNGAL MICROORGANISMS
Fungal organisms are eukaryotic with rigid cell walls
containing chitin, b-glucan, and mannoproteins. They may
be unicellular or multicellular and can be multinucleate.
They are grouped by morphology as either yeasts or fila-
mentous molds. Some organisms may have both morpholo-
gies. Reproduction occurs by the formation of spores
through mitosis; some also reproduce sexually. The fungal
cell wall takes up the methenamine silver stain, a useful
technique to identify the organisms in tissue sections. Many
fungi, except for Candida, do not take up the Gram stain
very well and may be missed if appropriate fungal stains are
not used. Within the cell wall is a sterol-containing cyto-
plasmic membrane. The major fungal sterol is ergosterol,
whereas cholesterol is the major sterol of human and other
mammalian cell membranes. The cytoplasmic membrane is
a major target for antifungal agents currently in use, includ-
ing azoles, allylamines, and polyenes.
Fungal organisms are ubiquitous in nature. Although
there are an estimated 250,000 fungal species, fewer than
150 have been described as human pathogens. Yeasts are the
most common fungal organisms that colonize and infect
humans. Of the hundreds of yeast species, however, only a
few (such as the genus Candida) cause human or animal dis-
ease. The genus Candida has approximately 200 species.
Candida species are found on many plants. Some Candida
species are also part of the normal flora within the gastroin-
testinal tract of humans and other mammals. Approximately
80% of normal healthy individuals carry one or more Candi-
da species. These are only a minor constituent of the gut
flora, however. Candida albicans represents one-half to two-
thirds of human yeast isolates; a dozen other species are also
occasionally present.
Nearly 20 Candida species have been described as
human pathogens. Virulence factors associated with patho-
genicity include rapid germination capacity, protease pro-
duction, adherence factors, complement protein-binding
receptors, phenotypic switching, and hydrophobicity. Viru-
lence factors have been reviewed elsewhere in detail [1–3].
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ABSTRACT
With improved control of cytomegalovirus infection, invasive fungal infections have become the leading cause of infec-
tious mortality after bone marrow transplantation (BMT). A number of changes in transplant practices have led to
changes in patterns of fungal infections: neutropenic episodes have been shortened through the use of hematopoietic
growth factors and peripheral blood as a source of stem cells. More potent immunosuppressive regimens, including T-
cell depletion techniques, have encouraged the use of alternate donor sources with greater numbers of transplant
recipients experiencing more prolonged and more profound immunodeficiency following engraftment. The advent of
new antifungal agents has led to a decline in Candida infections, but has encouraged the emergence of other less sus-
ceptible fungal pathogens. The development of molecular techniques to distinguish different fungal strains has led to
identification of nosocomial transmission as an unexpected means for the spread of fungal infections in BMT units.
These shifts in fungal infection patterns emphasize the need for infection control monitoring. The development of
more accurate diagnostic tools and the incorporation of new antifungal agents into practice are needed to further
improve outcomes.
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Molds ordinarily are not found in or on the human
body. Typically, the portal of entry is a break in the epider-
mis or inspiration into the nasal passages or respiratory
tract. The genus Aspergillus is the most common human
pathogen of the various molds. The most prevalent species
are Aspergillus fumigatus, A flavus, and A niger. Other
species, including Fusarium, Penicillium species, Alternaria,
Trichosporon and members of the Mucorales order, are also
increasingly being recognized as opportunistic human
pathogens. The dermatophytes, including Trychophyton and
Microsporum, organisms that have the capacity to digest ker-
atin, normally reside within soil habitats that can occasional-
ly infect keratinized tissues (hair, nails, and skin) but only
rarely invade tissue percutaneously.
Infection of humans by most fungal species is usually an
accidental occurrence; the human host is not a significant
reservoir. Thus, most fungal infections are not contracted by
person-to-person contact, but rather acquired through expo-
sure to a source in nature. In contrast, some fungi reside in
or on the human body (e.g., Candida). Recovery of such
organisms, therefore, has no clinical meaning other than in
the setting of immune compromise, where such organisms
may become opportunistic by invading host barriers, enter-
ing normally sterile tissue, and causing tissue damage.
Invasive infection occurs through an interplay of a
number of factors: host acquisition of the potential
pathogen, successful pathogen competition with microbial
competitors to grow in sufficient numbers to overcome
phagocytes, the inherent virulence properties of the patho-
genic organism to invade and cause tissue damage, and a
compromise in the integrity of the host’s normal defenses.
For invasive infection to take place, generally speaking, an
alteration in one or more of the above factors must take
place. For example, an exposure to substantial numbers of
certain exogenous organisms with appropriate virulence
properties might be sufficient to cause an infection in an
individual without immune compromise; inhalation of
Histoplasma or Coccidioides organisms by healthy individuals
in certain geographic locales would be examples of this. In
contrast, mucosal infection by commensal Candida organ-
isms only occurs if the competing endogenous bacterial
flora is suppressed by antibiotics; a compromise in host
defenses, such as mucosal damage along with neutropenia,
may be additionally required before a mucosal infection can
lead to a systemic infection.
Fungal organisms can be divided into three major cate-
gories according to their infection patterns [4]. The first
category, including fungi such as Coccidioides imitis, Blasto-
myces dermatidis, and Sporotrix schenckii cause infections in
individuals who do not appear to have an immune compro-
mise. Infections by these organisms do not generally occur
more readily in immunocompromised patients. The sec-
ond category of fungal organisms cause infections to a
greater degree in patients whose immunity is compro-
mised. Examples of such organisms include Cryptococcus
neoformans and Histoplasma capsulatum. The third category
of organisms appears to be most predominantly associated
with the treatment of an underlying disease rather than the
disease itself. Candida and Aspergillus organisms exemplify
this group of organisms. Neither Candida nor Aspergillus
infections were noted in leukemia patients or in patients
with other malignancies until the advent of chemotherapy
[5]. It is not the disease itself which predisposes the patient
to infection by these opportunistic organisms, but the
alteration of host defenses by treatment (e.g., mucositis
and neutropenia caused by chemotherapy, and fungal over-
growth in the gut facilitated by antibiotic suppression of
bacteria).
RISK FACTORS
Disease treatment rather than the underlying disease
condition itself has historically been the most prominent
factor associated with predisposition for the common inva-
sive fungal infections. Indeed, as noted above, the emer-
gence of opportunistic and fungal infections occurred only
after the introduction of cytotoxic therapeutic agents in the
1950s [5]. Before that, fungal infections in cancer patients
were rare. The contribution of leukopenia, damage to the
mucosa, and concomitant bacterial infection were suggested
in that initial report as factors associated with the occur-
rence of invasive fungal infection.
Historically, in both oncology practice as well as the
management of the BMT recipient, neutropenia has been
recognized as the major risk factor for all infectious com-
plications, including fungal infections. Both depth and
duration of neutropenia influence the risk for infection.
Fungal infections are rarely the cause of fever during the
first week of neutropenia. During the second and subse-
quent weeks of neutropenia, the risk of febrile fungal
infections increases incrementally [6]. Prolonged neu-
tropenia today remains a major risk factor in the BMT set-
ting. This is especially problematic in patients who fail to
engraft or in patients in whom the stem cell graft contains
low numbers of progenitors.
Today, with an emphasis on optimizing the progenitor
cell content of the stem cell graft, prolonged neutropenia is
less frequent than in former years. Thus, the risk for fungal
infection before engraftment is lower. This is illustrated by
two recent reports in which neutropenia was noted to be
present in only a minority of patients with invasive
aspergillosis; the vast majority of infections occurred after
engraftment [7,8].
Damage to the mucosa allows opportunistic organisms
with appropriate virulence factors to make the transition
from colonization to tissue invasion. The portal of entry for
Candida, a commensal organism normally residing in the
lumen of the gastrointestinal tract, is the gastrointestinal
tract. In contrast, Aspergillus, an airborne organism, enters
via the nasal passages and respiratory tract. For Candida, the
first step leading to infection is a proliferation of organisms,
made possible by antibiotic suppression of bacterial flora.
For Aspergillus, the first step is entry into the host. For both,
the crucial next prerequisite step is getting past the mucosal
barrier. This usually occurs only if there is damage to the
mucosal barrier to permit tissue invasion. In one treatment
center, the rates of invasive fungal infection in sequential
cohorts of leukemic patients receiving different chemo-
therapy regimens, each producing comparable neutropenic
intervals, were noted to be markedly different [9]. The
infection rate correlated with mucosal injury as assessed by
absorption of D-xylose [9,10].
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Mucositis, neutropenia, and antibiotic use are the major
risk factors prior to engraftment. Following engraftment
there is a second risk period for invasive fungal infection,
which, as noted above, has now emerged as the most
important risk period in allogeneic transplant recipients.
The use of corticosteroids and the occurrence of acute
graft-vs.-host disease (GVHD) are the major predisposing
factors [11–13]. Both GVHD and corticosteroid use are
associated with a suppression of cell-mediated immunity.
Corticosteroids also impair effective phagocytosis, and
GVHD is associated with an impaired reticuloendothelial
system, both representing important host defenses that are
also adversely affected.
The risk for infection correlates with both the dose of
steroids and duration of use. After matched unrelated donor
or mismatched family donor transplants, the risk for late
infection is substantial even in the absence of GVHD or
steroid use [14]. Although not formally assessed, this is pre-
sumably due to inadequate T-cell immune responses.
The use of T-cell depletion was expected to lead to lower
rates of fungal infection due to less GVHD and a resulting
decrease in corticosteroid use. In contrast, however, rates of
invasive fungal infection were found to be higher in several
series [11,15]. The greater risk for fungal, cytomegalovirus
(CMV), and Epstein-Barr virus infectious complications
observed after pan–T-cell depleted allografts emphasizes the
need to preserve certain protective subpopulations of lym-
phocytes and phagocytic precursors in the graft.
Prior Aspergillus infection has been noted in numerous
studies to be a risk factor for reactivation after repeated
chemotherapy courses [16] and subsequent BMT. Indeed,
the risk has been perceived to be so high for transplant-
related mortality that many centers in the past have regard-
ed this as a contraindication to transplantation [17–19].
Other risk factors have been described by various inves-
tigators. They include older age, type of transplant (alter-
nate donor vs. sibling-matched donor vs. autologous source
in descending order of risk), use of total-body irradiation,
low stem cell dose, CMV seropositivity, and prior splenecto-
my [8,11–14,20–23].
THE CHANGING EPIDEMIOLOGY OF FUNGAL
PATHOGENS
Candida albicans has historically been the leading fungal
pathogen in BMT patients. In recent years, however, a wide
range of nonalbicans Candida species have emerged as
important pathogens, now accounting for one-half of all
Candida infections [24]. Other organisms such as Fusarium,
Trychosporon species, and Alternaria are among the myriad
non-Candida organisms that have also emerged as pathogens
in the BMT patient population [25]. Their ascendancy has
been linked to a variety of health care measures [24,26,27]
(Table 1). Various innovations in transplant practices have
led to shifts in pathogens (Table 2).
Investigation of outbreaks of Candida infections by
recombinant DNA technology in several BMT centers have
led to the identification of a common source in some
instances [28–34]. Indeed, surveillance studies in critical
care units and BMT centers have shown contamination of
environmental surfaces and health care workers’ hands by
the same strain of organism. Although endogenous organ-
isms remain the major source for Candida infections,
increasingly important are exogenous organisms acquired
from the health care practice environment. Any outbreak
should be investigated with molecular techniques to identify
and correct at-risk practices [35–36].
High efficiency particulate air (HEPA) filters (or lami-
nar airflow) have reduced the risk for nosocomial acquisition
of Aspergillus spores [8,37–39]. Aspergillosis control, howev-
er, remains as challenging today as a decade ago. Many
transplant patients enter the hospital already colonized by
Aspergillus. Moreover, as we increasingly shift care to the
outpatient setting, the patient spends less time in the hospi-
tal and more time in outpatient clinics and offsite residential
areas, none of which have specialized air filtration systems.
The impact of these shifts in practice patterns on infection
rates and the pathogen spectrum remains to be seen.
Table 1. The link between emerging fungal pathogens and certain health
care practices
Fungal pathogen Health care practice implicated
C tropicalis Cytoreductive agents that cause mucositis
C krusei Fluconazole use
C glabrata Fluconazole use
C lusitania Polyene use
C parapsilosi Contamination of intravenous solutions and devices
Aspergillus Fireproofing material, hospital construction
Table 2. Innovations in transplant practices that have led to shifts in fungal infection patterns
Innovation Effect on host Fungal sequela
Hematopoietic growth factors Shorter time to neutrophil recovery Decrease in infection rate before engraftment
Use of peripheral blood as source of stem cells Shorter time to neutrophil recovery Decrease in infection rate before engraftment
T-cell depletion Slower recovery of cell-mediated immunity Increase in postengraftment infection rates
More potent immunosuppressive regimens Slower recovery of cell-mediated immunity Increase in postengraftment infection rates
Alternate donor transplants Slower recovery of cell-mediated immunity Increase in postengraftment infection rates
Fluconazole Reduction in C albicans infection rate
Increase in other fungal infections
Emergence of drug resistance (still 
uncommon)
Outpatient transplant activity Greater exposure to exogenous fungal organisms (? may lead to higher infection rates)
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MANIFESTATIONS AND DIAGNOSIS
The most common manifestation of Candida infection is
unexplained fever. Endophthalmitis, rare before engraft-
ment, is a more common sign of candidemia in the posten-
graftment period. The retinal lesions may be subtle and
should be investigated by indirect ophthalmoscopy. Macro-
nodular skin lesions, polyarthralgias or polymyalgias (due to
tissue invasion of joints and muscle), and azotemia (due to
an invasion of renal tubules) are occasional manifestations of
Candida fungemia. Persistent fever at engraftment and an
elevation of serum alkaline phosphatase may signal the pres-
ence of hepatosplenic candidiasis [40].
Pulmonary disease and, less commonly, sinusitis are
manifestations of aspergillosis. The propensity of Aspergillus
hyphae to invade blood vessels and cause pulmonary infarc-
tion produces the signs of pleuritic chest pain, hemoptysis,
localized wheezing, pleural friction rub, sinus tenderness,
nasal discharge, epistaxis, nasal eschar, and rales. Any of
these signs or symptoms in the setting of persistent fever
should lead to the suspicion of aspergillosis [41,42]. Pul-
monary infiltrates tend to be nodular and peripherally locat-
ed. Chest and sinus computerized tomography scans can
detect disease earlier than plain radiographs [43–45].
Primary cutaneous aspergillosis can occur at the exit site
or tunnel of a Hickman intravenous catheter. In one report,
outbreak of Aspergillus catheter infections during a period of
hospital renovation was caused by aerosolized spores being
introduced into the surgical wound [46]. Organisms were
recovered from air samples in operating rooms where
infected catheters were placed, but were not recovered from
other operating rooms.
Brain abscesses in the BMT patient are commonly due
to fungi. In one center, 92% of all cases of brain abscesses
were caused by fungi [47]. Aspergillus accounted for 58% of
cases and Candida for 33%. Bacteria were involved in fewer
than 10% of cases. Aspergillus brain abscesses usually
occurred concomitantly with pulmonary disease (87% of
cases). Candida brain abscesses were associated with
fungemia or neutropenia.
Surveillance cultures have limited utility [48–51]. They
are costly and time consuming. Although their negative pre-
dictive values are high, positive predictive values are low.
Because of these shortcomings, surveillance cultures have
largely been abandoned. With the emergence of antifungal
resistance, however, and a desire to target only individuals at
risk for antifungal therapy, one group has proposed the use
of fungal surveillance cultures to identify those at risk and to
exclude those not at risk (those with negative surveillance
cultures) to avoid unnecessary antifungal prophylaxis [52].
For those with positive surveillance cultures, preemptive
antifungal prophylaxis could be used to prevent invasive
infection. This would have the desirable benefit of providing
early therapy for those at risk while minimizing the hazard
for emergence of antimicrobial resistance, a result of wide-
spread indiscriminate antimicrobial usage. Such an approach
has not been formally tested prospectively.
Because of the subtlety of clinical signs and symptoms and
the unreliability of blood cultures, a variety of new techniques
have been investigated to improve the early documentation of
infection. Antigen assays for Cryptococcus and Histoplasma anti-
gens are currently available in the United States and can be
quite useful in detecting infections by both organisms. Unfor-
tunately, rapid diagnostic tests for the most common oppor-
tunistic infections in BMT patients, Candida and Aspergillus
infections, are not currently available. For these two
pathogens, assays for fungal antigens, antibodies, and metabo-
lites have generally failed to discriminate colonization from
infection or, where promising [53], are unavailable commer-
cially. Early work using polymerase chain reaction (PCR)
probes sensitive to Candida DNA are promising [54–56]. Both
antigen detection and PCR assays for Aspergillus are under
development [57–63]. Whether these will prove useful can
only be determined through wider testing of specificity and
sensitivity, and commercial development.
ANTIFUNGAL AGENTS
There are several classes of antifungal agents. These
include polyenes, nucleoside analogs, azoles, echinocandins,
pradamicins, allylamines, and nikkomycins. These have
recently been comprehensively reviewed [64]. The fungal
targets for various agents are listed in Table 3.
Agents in current use
Amphotericin B, a polyene antifungal, is a lipophilic rod-
shaped molecule that acts on the cytoplasmic membrane by
binding to sterols such as ergosterol to increase membrane
permeability. Loss of intracellular potassium and other mole-
cules then ensues which leads to cell death. Resistance is
uncommon, but can occur by alteration of the membrane
sterol content [65–67]. Certain fungal species, most notably
C lusitaniae, are frequently resistant to amphotericin B [68].
Unfortunately, amphotericin B has a very narrow thera-
peutic ratio. Infusional toxicities are quite frequent and can
be quite severe. They include fever, shaking chills, and, occa-
sionally, respiratory distress, hypoxia, and hypotension.
Nephrotoxicity can also be quite problematic and can, on
occasion, necessitate hemodialysis [69]. Wasting of potassi-
um and magnesium, anemia, hepatotoxicity and other side
effects can also occur. Most toxicities are reversible with ces-
sation of therapy. There are no acceptable pharmacologic
assays to monitor amphotericin B therapy. Generally, doses
of 0.3–0.6 mg · kg21 · day21 are used for Candida infections.
Higher doses such as 0.75–1.0 mg · kg21 · day21 are generally
used for Aspergillus infections. Dose adjustments must be
made if toxicities occur.
To improve the therapeutic ratio, lipid formulations of
amphotericin B have been developed. Three products are
Table 3. Fungal targets for antifungal therapeutics
Fungal targets Antifungal agents
Cell wall Echinocandins
Pradimicins
Nikkomycins
Cell membrane Polyenes (amphotericin B, nystatin)
Azoles (fluconazole, itraconazole)
Allylamines
DNA and RNA synthesis Flucytosine
g f f
59B B & M T
now licensed in the United States—amphotericin B in lipid
complex (ABLC), liposomal amphotericin B, and ampho-
tericin B in colloidal dispersion (ABCD). The pharmacolog-
ic properties of these agents have been reviewed [70–74]. A
variety of studies have demonstrated that these agents can
be given in up to 10 times higher doses than the parent
compound with a lesser degree of nephrotoxicity. Infusional
side effects still occur; there appear to be some differences
in the rates of these infusional toxicities with the three
agents, but a direct comparison has not been performed.
These agents have been successful in treating patients with
invasive fungal infections in which amphotericin B has failed
or caused intolerance [75,76]. However, prospective ran-
domized studies of the lipid formulations of amphotericin B
have failed to produce consistent and substantial improve-
ments in efficacy when compared with amphotericin B as
primary therapy for invasive fungal infections [77,78]. The
improved therapeutic ratio is thought to be due to higher
concentrations of the drug reaching target tissues, such as
lung, liver, and spleen, with lower concentrations of the
drug in the kidney (the site of major toxicity). The mecha-
nisms by which the lipid formulations of amphotericin B
actually deliver the active drug to the fungal cell membrane
has not yet been elucidated [70].
Delivery of amphotericin B to the nasal passages and res-
piratory tract by a nasal spray or aerosolization is intended to
deliver high concentrations to suppress growth on mucosal
surfaces [79–81]. Although appealing, one prospective ran-
domized trial of aerosolized amphotericin B failed to demon-
strate a reduced incidence of pulmonary aspergillosis [82].
Flucytosine is a pyrimidine analog that is deaminated to
5-fluorouracil within the fungus and then converted to 5-
fluorodeoxyuridylic acid monophosphate, which in turn
inhibits thymidylate synthetase and thereby interferes with
DNA synthesis. Drug resistance develops by loss or muta-
tion of any of the enzymes that activate the drug and can
occur readily if flucytosine is used alone; for that reason, it is
generally used in combination with amphotericin B [67]. A
combination of amphotericin B and flucytosine has been
widely adopted as a standard treatment for cryptococcal
meningitis. This combination treatment has also been advo-
cated for aspergillosis and refractory systemic Candida infec-
tions, but there are no controlled trials for these latter two
situations. Toxicities that can occur include both mucositis
and myelosuppression (toxicities frequently observed with
5-fluorouracil), obvious disadvantages since both can exacer-
bate the deficiencies in host defenses that predisposed the
patient to infection in the first place. Toxicity appears to be
associated with excessive serum levels. Blood levels between
50 and 100 mL/mL are appropriate therapeutic targets.
Azole antifungals, which include miconazole, ketacona-
zole, itraconazole, and fluconazole, inhibit 14-alpha-demethy-
lation of lanosterol by binding to fungal cytochrome P450
enzymes. Ergosterol in the cytoplasmic membrane is reduced,
leading to increased permeability and inhibition of cell growth.
Toxicities of azoles tend to be less frequent and milder
than polyene toxicities. Hepatoxocity can occur and infre-
quently can be serious. Fluconazole is available in both oral
and intravenous formulations. Its bioavailability is excellent
(exceeding 90%) with little variability by ingestion of food
or intragastric pH. Peak concentrations occur 1–2 hours
after ingestion. Excretion is mostly via the kidneys. Adult
doses of 100 mg/day are used to treat mucosal infections,
and 400 mg/day for systemic infections. Doses up to 1200
mg/day are well tolerated. Fluconazole is very active against
most Candida species and has been shown to be as effective
as amphotericin B for systemic Candida infections [83,84].
Fluconazole also has excellent activity against Cryptococcus
and Coccidiodes, and less activity against several other fungal
species [64].
Itraconazole is currently available only as an oral agent.
Bioavailability of itraconazole is variable in BMT patients
[85–87]. A new oral cyclodextrin formulation of itraconazole
improves the bioavailability [88,89]. Preliminary data in one
center demonstrated the achievement of therapeutic plasma
concentrations early after transplant [90]. Some centers have
encountered patient tolerance difficulty early in the trans-
plant treatment course. More information is clearly needed.
Resistance to azoles has been uncommon, but it has
been increasing in recent years. There are several different
mechanisms of development of azole resistance. For flu-
conazole, three general mechanisms have been described.
One mechanism is an alteration in the target enzyme, 14-
alpha-demethylase, making it less susceptible to inhibition
by azoles. A second mechanism is a reduction in drug accu-
mulation either by reduced uptake or increased efflux. A
third mechanism is a deficiency of delta 5, 6 desaturase. This
deficiency leads to production of 14-methylfecosterol,
which permits retention of viability even when 14-alpha-
demethylase is inhibited. Some fungal species are natively
resistant to fluconazole. C krusei is such an organism. Stud-
ies indicate that there are qualitative differences between the
14-alpha-demethylase of C albicans and C krusei that lead to
a low susceptibility to inhibition by fluconazole [91]. In
other organisms (e.g., C glabrata), mutations may occur dur-
ing a course of treatment, leading to the emergence of drug
resistance in initially susceptible organisms. Reduced drug
accumulation was noted in one study to account for itra-
conazole resistance to C krusei [92].
The emergence of fluconazole-resistant organisms as
pathogens was initially seen in patients with HIV infection
receiving chronic suppressive therapy. Most of these organ-
isms were mucosal pathogens and infrequently caused sys-
temic infection. However, in recent years, systemic Candida
infections have been noted in leukemia and BMT patients
who had been receiving the agent for a short period of time
[93,94]. With the increasing use of fluconazole and the
recent recognition of the potential for nosocomial transmis-
sion of organisms such as those noted above, vigilance must
be maintained and may necessitate restrictions on use. The
emergence of drug resistance may have profound effects on
antifungal therapeutic strategies [95,96].
Agents under development
Both the positive attributes (excellent tolerance) and the
shortcomings (limited antifungal spectrum in the case of flu-
conazole and variable bioavailability and frequent drug
interactions in the case of itraconazole) have encouraged the
development of other azole compounds with broader spec-
trum and more desirable pharmacokinetic properties. Sever-
al are currently in development. Two triazoles are currently
in clinical trials. Both have excellent bioavailability, oral and
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intravenous formulations, and are active against the major
fungal pathogens. Voriconazole has broad spectrum antifun-
gal activity not only against C krusei, C glabrata, and
Aspergillus species—organisms not covered by fluconazole—
but also against a variety of other emerging pathogens
[97–100]. Animal models have shown in vivo efficacy against
such pathogens, including fluconazole-resistant C albicans
isolates [101]. Several clinical trials have demonstrated
excellent patient tolerance as well as clinically relevant drug
activity against Aspergillus [101–104]. Temporary visual side
effects have been noted in some patients.
SCH56592 is another triazole with broad spectrum
activity (including fluconazole-resistant C albicans strains)
with activity against Aspergillus and other filamentous fungi
[105–110]. Its mechanism of action is similar to that of other
azoles. There are some drug interactions (such as phenytoin
and rifabutin) and some variability of absorption with eat-
ing. Some transient hepatotoxicity has been noted in clinical
trials. In general, however, it has been well tolerated. Ongo-
ing clinical trials are under way.
The echinocandin group of molecules are amphophilic
lipopeptides. They act by inhibiting fungal b[1,3] glucan
synthetase, an enzyme at the cell membrane. This inhibition
eventually results in lysis of the fungal organism by interfer-
ing with synthesis of chitin, an important cell wall con-
stituent. Certain members of this family show synergy with
amphotericin B and lack of cross resistance with the azoles. A
broad spectrum of antifungal activity has been noted [111].
The pradimicins and benanomycins have benzonaph-
thacene quinone frames that act by complexing with the
mannoproteins in the cell wall that lead to leakage of intracellu-
lar molecules and cell death. These have been shown to have a
broad spectrum of antifungal activity in preclinical trials [112].
The allylamines (terbinafine) are excellent agents espe-
cially active against dermatophytes and are used topically.
Allylamines have demonstrated in vitro activity against a
broad range of organisms, but preclinical in vivo models
have failed to show consistent activity.
Liposomal nystatin, a lipid formulation of this widely
used oral and topical polyene antifungal, has been shown to
have broad spectrum activity against systemic pathogens and
good tolerance in preclinical models [113]. Clinical trials are
currently under way [114].
The nikkomycins are pyrimidine nucleosides that are
structurally similar to precursor substrates for chitin and act
as competitive inhibitors of the fungal chitin synthase
enzymes [115]. Activity against several important fungal
pathogens has been noted [116]. Synergy with several other
classes of antifungal agents gives promise that this might be
particularly useful in combination therapy.
STRATEGIES TO CONTROL INFECTION
Prophylaxis
Strategies to reduce infection include measures to
reduce host acquisition of the fungal organisms, use of
agents to suppress organism growth, and efforts to bolster
host defenses (Table 4). Clearly, infection control measures
to reduce nosocomial transmission are of paramount impor-
tance. Air filters are crucial for prevention of patient expo-
sure to exogenous organisms, such as aspergillosis [8,37–39].
Hand washing and exercise of universal precautions are the
key to minimizing the spread of endogenous organisms,
such as Candida, from patient to patient [28–34]. As noted
earlier, investigation of any cluster of infections should be
carried out by an infection control team in cooperation with
the transplant clinicians [35,36]. This investigation may
require molecular typing techniques to distinguish strains,
in order to determine if nosocomial transmission may be
playing a role. The transplant clinician must be vigilant for
changes in transplant practice associated with infection clus-
ters (Tables 1 and 2) [24,26,27].
Agents such as nystatin, clotrimazole, and ketoconazole
have been used to suppress colonization and thereby reduce
infections. These have had only marginal success. Intra-
venous miconazole, an imidazole, was found in a random-
ized trial to reduce the risk for fungal infections [117], but
its narrow spectrum of activity and toxicity profile limited its
widespread use. Fluconazole, a triazole, has been shown in
randomized trials to reduce the incidence of fungemia
[118,119], deaths attributable to fungal infection, and in one
study overall mortality [119]. In a multivariate analysis of
factors associated with outcome after unrelated donor trans-
plants, fluconazole use was found to be an independent fac-
tor associated with survival [120]. Several other studies have
shown fluconazole to be superior to oral amphotericin B,
nystatin, or clotrimozole [121,122].
Unfortunately, fluconazole’s spectrum of antifungal
activity is limited. Its most notable shortcoming is its lack of
activity against Aspergillus. C krusei is natively resistant to
fluconazole, and sporadic breakthrough infections have been
occasionally noted. In several centers, outbreaks of C krusei
occurred [123,124]. Some strains of C glabrata are resistant.
Sporadic infections by C glabrata and an outbreak in BMT
patients receiving fluconazole have been reported [125].
Two centers have described breakthrough C parapsilosis
infections in BMT centers using fluconazole [126,127]. This
was unexpected since C parapsilosis is ordinarily susceptible
to fluconazole.
One randomized trial of itraconazole prophylaxis using
the capsule formulation in patients with hematologic
malignancies failed to show any significant benefit [128].
Studies evaluating the cyclodextran formulation have yet
to be reported.
Amphotericin B given prophylactically to patients with
prior aspergillus infection has been found to be effective in
patients undergoing bone marrow transplantation
Table 4. Goals of antifungal prophylaxis
Reduce acquisition of pathogen
Environmental decontamination
Reduction of nosocomial transmission
Suppression of colonizing pathogens
Pharmacologic agents
Enhance host resistance
Hematopoietic growth factors
Granulocyte transfusions
Stem cell infusions
Mucosal stem cell growth factors
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[129–132]. Prior aspergillosis was once grounds for exclu-
sion from consideration for bone marrow transplantation;
today most centers proceed with transplant under antifungal
prophylaxis [133]. Resection of a localized lesion is recom-
mended when possible [133–135].
Because of toxicity with full-dose amphotericin B, pro-
phylaxis with low doses of amphotericin B has been tested:
nephrotoxicity is less, but infusional toxicities remain. Two
historical comparisons, one during pre-engraftment the other
postengraftment, have suggested a benefit [136,137]. In the
latter study, a greater incidence of GVHD was noted.
Cyclosporin levels were lower in patients receiving ampho-
tericin B. In a randomized study [138], amphotericin B given
at a dose of 0.1 mg · kg21 · day21 was well-tolerated without
significant nephrotoxicity. Overall, the rate of fungal infection
in the amphotericin B group was lower than that in the place-
bo group. However, there was a very low rate of Aspergillus
infection (there was only one infection by Aspergillus in the
group that had received amphotericin). The utility of this
approach in groups at higher risk remains uncertain, however.
In another randomized trial in autograft recipients [139], the
rate of fungal infection in the control group was only 1%, too
low to assess the efficacy of the study regimen.
These data suggest that low dose amphotericin B can be
given with little nephrotoxicity. Unfortunately, infusional
toxicities remain problematic. The randomized trials have
not demonstrated a consistent benefit, and most infections
prevented in the sole randomized trial showing a benefit
[138] could have been prevented by fluconazole. Break-
through Aspergillus infections in patients receiving higher
doses of amphotericin B (0.5 mg · kg21 · day21), and the
emergence of polyene resistance in centers where ampho-
tericin B and nystatin use is widespread [140] make this
approach questionable as to whether it offers any real bene-
fit against Aspergillus and other mold infections.
In order to capitalize on the lower risk for nephrotoxici-
ty of the lipid formulations of amphotericin B, a randomized
trial was conducted evaluating liposomal amphotericin B in
BMT patients [141]. Although there was a lower rate of col-
onization in patients receiving liposomal amphotericin B,
there was no significant reduction of invasive infections.
Unfortunately, the sample size was small and a benefit might
have been missed.
Although conceptually appealing, efforts to bolster host
defenses have been largely limited. Several investigational
measures will be discussed below.
Treatment
Amphotericin B has been the treatment of choice for
invasive fungal infection for many years. Doses of 0.3–0.7
mg · kg21 · day21 are generally given for Candida infections;
doses of 0.7 to 1.0 mg · kg21 · day21 for invasive aspergillus
and other mold infections. The use of combination therapy
with flucytosine is supported by some animal models and
clinical evidence for cryptococcal disease. An in vivo murine
model has also suggested synergy between amphotericin B
with rifampin or flucytosine for aspergillosis [142]. In a
review of more than 2,000 cases of aspergillus infections,
patients receiving amphotericin B plus either rifampin or
flucytosine had slightly greater response rates [134]. Preclini-
cal testing of combinations of polyenes and azoles have indi-
cated synergism in some cases and antagonism in others.
Thus, their use in combination should be avoided outside of
a clinical trial.
There are a number of drawbacks to amphotericin B
treatment. The failure rate is high: 73–85% [11,118,143]
in Candida infections and 75–95% [11,12,144] in
Aspergillus infections.
There are several reasons for the high failure rate for
treatment. First and foremost is delay in starting treatment.
Manifestations of infection are frequently subtle and often
overlooked until the burden of organisms is substantial and
the prospects for eradication are poor even in the best of
circumstances. The burden of Candida organisms influences
the outcome: for example, in one report there was a 39%
mortality from Candida fungemia alone in contrast to 90%
when fungemia was accompanied by tissue invasion [11]. In
another study, mortality from non-Candida infections was
0% in patients with only isolated fungemia, in contrast to
41% in patients with single organ or site infection, and 83%
in patients with disseminated infection [144].
Amphotericin B’s narrow therapeutic ratio is especially
problematic in the allogeneic BMT patient where mainte-
nance of immunosuppressive treatment is important for con-
trol of GVHD. Because of the frequent occurrence of
nephrotoxicity with either cyclosporine or amphotericin B
individually and an almost certain compromise in renal func-
tion when both are used concomitantly [69,145], the clini-
cian is often faced with the difficult dilemma of choosing
between dose reduction of the immunosuppressive regimen
or reducing the dose of the antifungal therapy. Either action
may increase the hazard for a life threatening consequence.
The ability of the host to assist in clearance of fungal
pathogens is also paramount for recovery. Certainly the
inferior capacity to mount an immune response is contribu-
tory to the lower rate of survival from non-Candida invasive
infection in allograft patients (15%) compared to autograft
patients (35%) [25]. Similarly, an important predictor of
outcome is the physiologic status of the patients (as meas-
ured by the Acute Physiology, Age, Chronic Health Evalua-
tion [APACHE] II score) at the onset of infection [146].
Without restoration of the host’s defenses, some have
argued with good cause, few patients will survive an invasive
fungal infection [147].
Other obstacles to successful treatment include limited
spectrum of activity of antifungal agents. For example, flu-
conazole has poor activity against C krusei, many strains of C
glabrata, and Aspergillus species. Amphotericin B has limited
activity against Fusarium and C lusitania.
Bioavailability is problematic for several agents.
Although itraconazole has excellent activity against
Aspergillus species, its bioavailability is erratic, as noted earli-
er. Monitoring of blood levels is important since its effec-
tiveness correlates with plasma levels [86]. The use of
antacids or H2 blockers should be avoided since gastric
acidity is necessary for absorption of itraconazole. In addi-
tion, rifampin should be avoided since it may lead to low
itraconazole plasma concentrations.
Less toxic alternatives to amphotericin B have now been
shown to be effective for the treatment of invasive Candida
infection. In comparative trials in both neutropenic and
non-neutropenic patients, fluconazole was found to be as
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efficacious as amphotericin B in the treatment of hematoge-
nous Candida infection but with less toxicity [83,84]. That
survival was not improved in these trials, since toxicity did
not limit the use of antifungal therapy, is disappointing. In
another randomized trial, ABLC was also found to be as
effective as amphotericin B but less toxic [77]. The lipid for-
mulations of amphotericin B appear to be quite promising
in the treatment of aspergillus and other mold infections, as
noted earlier. Several historical case control studies have
indicated at least comparable survival with less nephrotoxici-
ty [75,76,148,149]. A recent randomized trial comparing
ABCD with amphotericin B showed equivalent efficacy with
a decrease in nephrotoxocity [78].
Removal of central venous catheters in Candida fungemia
has been debated. Several studies support both sides of the
issue as to whether catheters should be routinely removed in
all patients with fungemia. However, it is clear that any
patient not responding promptly to antifungal therapy with
persistent positive cultures should have the catheter removed.
The role of surgical resection of infarcted tissue in
aspergillosis has similarly been debated. Certainly, there are
selected patients in which resection can improve prospects
for long-term control [134]. Patients with Aspergillus sinusi-
tis may similarly benefit from drainage and irrigation of the
infected sinus and debridement of soft tissue or bony infarc-
tion [134].
Empiric therapy
Because of the difficulty in accurately documenting the
early course of invasive fungal infections, and the poor
results when treatment initiation is delayed, the use of
empiric antifungal therapy has been embraced, as has the use
of empiric antibacterial therapy for neutropenic fever. Two
studies have supported empiric fungal therapy in oncology
practice for treating persistent fever during neutropenia 4–7
days after initiation of antibacterial therapy [150,151].
The shortcoming of this strategy is the toxicity caused by
amphotericin B. Certainly, fluconazole could be used in this
fashion instead of prophylactically, but with the gaps in its
coverage, important fungal pathogens would not be treated.
The variability and delay in achieving therapeutic concentra-
tions of itraconazole make that agent unsatisfactory.
The lipid formulations of amphotericin B do offer an
acceptable alternative to the parent compound as demon-
strated by several Phase II and prospective randomized trials
[145,148,149,152–154]. These studies show that consider-
ably less nephrotoxicity is observed when one of the lipid
formulations is substituted for amphotericin B; efficacy is
comparable. The major shortcoming of wholesale substitu-
tion of one of the lipid formulations for the parent com-
pound of amphotericin B is the extraordinary difference in
cost. Several studies, however, emphasize the especially high
risk for nephrotoxicity [155,156] and hemodialysis [69,157]
in the BMT recipient. Certainly, hemodialysis and extra time
spent in the hospital are costly and can easily offset any sav-
ings gained by avoidance of a costly pharmaceutical. Careful
cost effective analyses are needed to help guide clinical deci-
sions as to which patients and at what time substitution of
the lipid formulation of amphotericin B is appropriate.
Several antifungal strategies are under development
(Table 5). Current and future studies will determine what
role these will have in the BMT patient.
STRATEGIES TO BOLSTER HOST DEFENSES
Improvement of host defenses is among the least devel-
oped strategies for fungal infection control and yet, ulti-
mately, the most vital determinant of infection control.
Granulocyte colony-stimulating factor (G-CSF) and granu-
locyte-macrophage colony-stimulating factor (GM-CSF)
have been quite successful in speeding neutrophil recovery
in nontransplant chemotherapy-induced myelosuppression
and in the transplant setting. There was considerable hope
that their use would lead to a reduction in invasive fungal
infection. Unfortunately, the effect of these molecules on
bacterial and fungal infection rates has been quite disap-
pointing [158]. Indeed, none of 19 randomized clinical trials
of these molecules in BMT recipients noted a reduction in
fungal infection. Further, there is no evidence that ampho-
tericin B use for suspected infection was altered. That those
trials were not designed to address this question could be
argued, and certainly that was the case. However, if there is
a benefit, it probably must be small.
Granulocyte transfusions in some cases have been use-
ful as adjuncts to antifungal agents. Pretreatment of donors
by colony stimulating factors (G-CSF, GM-CSF, or macro-
phage-CSF) before leukapheresis yields markedly greater
numbers of neutrophils. Such “enhanced” granulocyte
transfusions can be used as prophylaxis or as treatment
[159–161]. Alternatively, G-CSF or GM-CSF can be given
to the patient as an adjunct to antifungal therapy. GM-CSF
is particularly attractive since in vitro assays suggest that it
improves the functional activity of monocytes and macro-
phages in addition to its stimulatory effects on neutrophils.
As adjuncts to antifungal therapy for treatment of infection,
the results to date have similarly been disappointing [158].
Gamma interferon improves the functionality of neu-
trophils against aspergillus in patients with chronic granulo-
matous disease [162]. This cytokine may be useful as an
adjunct to antifungal therapy or as prophylaxis.
Restoration of mucosal integrity after chemotherapy-
induced injury and prevention of severe mucosal injury are
desirable goals. Several approaches have been evaluated in
Table 5. Treatment strategies under development
Strategy Reference number
Molecular tools to identify fungal strains causing outbreaks 28–36
Rapid diagnostics for Candida 53–56
Rapid diagnostics for Aspergillus 57,63
Fluconazole as treatment of candidosis 83,84
Lipid formulations of amphotericin B 70–78,141
148,149,152,154
Cyclodextrin formulations of itraconazole 88–90
Aerosolized amphotericin B 79–82
Wider spectrum triazoles 97–110
Enhanced granulocyte transfusions 159–161
Gamma interferon 162
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preclinical models. Keratinocyte growth factor (KGF) has
been noted to affect proliferative activity in mucosal epithe-
lial cells in cell lines and animal models [163–165]. In an
animal model of radiation and chemotherapy-induced gas-
trointestinal mucositis and mortality, KGF was found to
have protective effects with decreases in weight loss and
mortality, and a marked increase in the intestinal prolifera-
tive crypt activity during the healing phase. In another 
animal model, KGF was found to prevent GVHD while
preserving graft-vs.-leukemia after experimental allogeneic
BMT [166]. This was thought to be through preservation of
gut mucosal integrity reducing translocation of lipopolysac-
charide from the gastrointestinal lumen into the circulation
and, thereby, reduction of other proinflammatory cytokines
that incited GVHD. KGF is currently undergoing clinical
trials to assess tolerability and protective effects on the
mucosal barrier function.
Transforming growth factor (TGF)-b has been shown
to inhibit the cycling of human buccal mucosal epithelial
cells. Pretreatment of cells with TGF-b prevents them from
toxicity mediated by a variety of chemotherapy agents [167].
Unfortunately, this is currently not under clinical develop-
ment. Interleukin-11, a molecule now Food and Drug
Administration–approved for speeding thrombopoietic
recovery after chemotherapy-induced thrombocytopenia,
also has restorative effects on the mucosa. It has been noted
to inhibit apoptosis and stimulate repair of intestinal crypt
cells following cytoreductive therapy in preclinical models.
These effects have resulted in reduced mucositis from
chemoradiation injury in vitro and in animal models
[168–170]. Whether this will have beneficial effects clinical-
ly remains to be seen.
Several trials with myeloid growth factors applied topically
to the mucosa have been disappointing. One study of topical
oral G-CSF, however, had a borderline significant benefit [171].
CONCLUSION
Fungal infections pose an important challenge for the
BMT clinician. The major risk for fungal infections has
shifted from preengraftment to the postengraftment period,
with GVHD and the use of systemic corticosteroids emerg-
ing as the major host risk factors for infection. The clinician
now faces a larger array of fungal pathogens. Although less
toxic alternatives to amphotericin B have been evaluated as
treatment in randomized trials, outcomes have still not
improved. Clearly there is a need for more accurate diag-
nostic tests to permit initiation of treatment earlier in the
course of infection, when the burden of organisms is more
manageable. Until such time, clinicians should strongly con-
sider preventive measures. Reduction in the acquisition of
organisms by HEPA filters, the avoidance of invasive proce-
dures, and vigorous infection control maneuvers to prevent
nosocomial transmission from patient to patient must be the
mainstays of any approach to control these infections. Sup-
pression of colonizing organisms by pharmacologic agents
reduces the threat of systemic infection from certain fungal
species but not others. New formulations of agents such as
itraconazole are being evaluated to improve bioavailability
and thus enhance their prospects as a prophylactic agents.
Amphotericin B lipid formulations of offer a less toxic
means of administering high doses of amphotericin B. New
triazoles with a wider spectrum of action and excellent
bioavailability are entering clinical trials. A variety of other
classes of antifungal molecules are being evaluated. Strate-
gies to bolster host defenses by hematopoietic growth fac-
tors, cytokines with immunomodulatory or mucosal effects,
and primed granulocyte transfusions all hold promise to
reduce the host vulnerability to these infections. Combining
these different modalities offers hope for improved control
of fungal infections.
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